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1.0 Abstract 
Approximately one third of patients presenting with a first episode of psychosis need long-term 
support, but there is a limited understanding of the sociodemographic or biological factors that 
predict this outcome. We used electronic health records from a naturalistic cohort of consecutive 
patients referred to an early intervention in psychosis service to address this question. We extracted 
data on demographic (age, sex, ethnicity and marital status), immune (differential cell count 
measures and C-reactive protein (CRP)) and metabolic (cholesterol, triglycerides, glucose, glycated 
haemoglobin, blood pressure, body mass index (BMI)) factors at baseline, and subsequent need for 
long-term secondary (specialist) psychiatric care. Of 749 patients with outcome data available, 447 
(60%) had a good outcome and were discharged to primary care, while 302 (40%) required follow-
up by secondary mental health services indicating a worse outcome. The need for ongoing secondary 
mental healthcare was associated with high triglycerides levels (adjusted odds ratio/OR=7.32, 95% 
CI 2.26-28.06), low basophil:lymphocyte ratio (adjusted OR=0.14, 95% CI 0.02-0.58), and high 
monocyte count (adjusted OR=2.78, 95% CI 1.02-8.06) at baseline. The associations for baseline 
basophil (unadjusted OR=0.27 per SD, 95% CI 0.10-0.62) and platelet counts (unadjusted OR=2.88, 
95% CI 1.29-6.63) attenuated following adjustment for BMI. Baseline CRP levels or BMI were not 
associated with longer-term psychiatric outcome. In conclusion, we provide evidence that 
triglyceride levels and several blood cell counts measured at presentation may be clinically useful 
markers of long-term prognosis of first episode psychosis in clinical settings. These findings will 
require replication.
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2.0 Introduction
Schizophrenia is a serious mental illness affecting approximately 40 million people globally (Saha et 
al., 2005). Early intervention in psychosis currently represents the gold standard of care for people 
presenting with a first episode of psychosis (FEP) (McGorry, 2015). In this model, a specialised 
multi-disciplinary team delivers pharmacological and psychological interventions, family and social 
support, support with employment, and physical health care checks for up to 5 years to patients 
diagnosed with a FEP, thus reducing the duration of untreated psychosis (Marshall et al., 2005) and 
improving long-term psychiatric outcomes (Penttilä et al., 2014; Perkins et al., 2005). FEP patients 
receiving care from EI services (EIS) have a generally positive outlook. Previous evidence suggests 
42% as having a “good outcome” such as remission, and 27% as having “poor outcomes” such as 
needing further secondary (specialist) care input (Menezes et al., 2006). Furthermore, 13.5-19.2% 
show the best possible outcome, i.e. full recovery (Jääskeläinen et al., 2013; Wunderink et al., 2009).
It is currently difficult to predict the prognosis of an individual patient with FEP at the time of 
presentation to an EIS. Existing studies have reported certain baseline factors to be associated with 
subsequent poor clinical course/outcome, such as long duration of untreated psychosis(Penttilä et al., 
2014; Perkins et al., 2005), poor pre-morbid functioning (White et al., 2009), prevailing baseline 
negative symptoms (White et al., 2009), lower IQ (Leeson et al., 2009) and persistent substance 
abuse (Barnett et al., 2007). 
Biomarkers could aid better prediction of treatment outcomes in patients with FEP. There is cross-
sectional evidence that drug-naïve FEP patients show evidence of inflammation, including elevated 
C-reactive protein (CRP) and inflammatory cytokine levels (Pillinger et al., 2018), elevated 
neutrophil and monocyte counts (Jackson and Miller, 2019), and elevated neutrophil to lymphocyte 
ratio or NLR (Moody and Miller, 2018). Similarly, meta-analytic evidence suggests metabolic 
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alterations in FEP, such as impaired glucose tolerance, insulin resistance (Perry et al., 2016), and 
high triglycerides (Pillinger et al., 2017). Studies showing a longitudinal association between 
childhood inflammation and future risk of psychosis in adulthood provide evidence that raised 
inflammatory markers in patients with psychosis is not solely a consequence of their illness 
(Khandaker et al., 2014; Metcalf et al., 2017; Wium-Andersen et al., 2014). Furthermore, Mendelian 
randomisation studies also support a potentially causal association between lymphocyte counts, IL-6 
and CRP levels and psychosis (Astle et al., 2016; Hartwig et al., 2017; Khandaker et al., 2017). 
Recently, Nettis and colleagues have reported that a combination of inflammatory (high CRP) and 
cardiometabolic markers (elevated triglycerides and body mass index (BMI)) at baseline could help 
predict clinical outcomes at follow-up at about one year in a small sample of 42 FEP patients (Nettis 
et al., 2019). This study aims to extend these potentially clinically useful findings by including a 
larger sample of patients from an EIS, including a larger and more detailed set of predictor variables, 
and by extending the length of follow-up.
In this study, we examined longitudinal associations between immune and cardio-metabolic markers 
at baseline and clinical outcomes at 1-5 years in FEP patients using real-world clinical data from 
electronic health records (EHR) from an EIS in England. We also explored potential correlations 
between cardiometabolic and immune markers in FEP.
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3.0 Methods
3.1 Setting and sample selection
CAMEO is a specialist EIS for people with FEP living in Cambridgeshire, Fenland and 
Peterborough, geographically defined areas in East of England. Referrals are accepted from multiple 
sources including general practitioners, mental health services, school and college counsellors, 
relatives, and self-referrals. People referred to CAMEO receive a comprehensive clinical assessment 
and are offered a physical examination and venepuncture for inflammatory and cardiometabolic 
markers. This study includes all patients who have been accepted by CAMEO between January 2013 
and November 2019. The CAMEO service accepts patients who present with a psychotic episode for 
the first time, or if previous psychosis was either untreated or treated with antipsychotic medication 
for <6 months. It accepts people presenting with psychotic symptoms from any cause, including 
drug-induced psychoses and affective psychoses (including ICD-10 codes F06.0-2, F20-F31, F32.3, 
F33.3, F53.1). The EIS patients’ age range was 14-35 years until 1 April 2016, then became 14–65 
years. All FEP patients were followed up for up to 3 years. We excluded patients who had not 
completed the EIS intervention or had moved out of area, as these groups did not have outcome 
variables available.
For this study, FEP patients were identified by carrying out an anonymised search of EHRs held by 
Cambridgeshire and Peterborough NHS Foundation Trust (CPFT), the UK National Health Service 
(NHS) provider of mental health services to the region. These patients received EI from CAMEO 
between 2013 and November 2019 (inclusive). Patient records were de-identified electronically 
using the Clinical Records Anonymisation and Text Extraction (CRATE) tool purpose built for 
research based on EHR data (Cardinal, 2017), and transferred into a research database with NHS and 
institutional approvals (UK NHS National Research Ethics Service references 12/EE/0407 and 
17/EE/0442). 
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3.2 Extraction and coding of categorical information
3.2.1 Sociodemographic information
For each patient, we extracted the following categorical information directly from the database: 
approximate date of birth/ age in years, sex, ethnicity, marital status, EIS involvement start and end 
dates.
3.2.2 Primary outcome (psychiatric illness course)
Patients were categorised into two groups reflecting their psychiatric illness course, based on their 
clinical destination after discharge from the EIS:
 Discharged to primary care with no onward referrals to community mental health teams 
upon discharge, or within 2 years of discharge (so-called good outcome/ illness course). 
 Continued involvement of secondary mental health services including one or more referrals to 
community mental health teams, crisis team or hospitalization within 2 years of discharge 
(so-called poor outcome/ illness course).
3.2.3 Exploratory outcomes (ICD-10 diagnosis, intensity of care need and baseline severity measures)
ICD-10 psychiatric diagnoses assigned by clinicians were used as secondary outcome measures. We 
used three main categories of diagnoses: F2x (schizophrenia, schizotypal, delusional, and other non-
mood psychotic disorders), F3x (mood disorders), or Other/NA (any other diagnosis, or no coded 
diagnosis). As many patients had more than one recorded diagnosis, we used the ICD-10 hierarchical 
method to assign one “main diagnosis” per patient, as follows: organic mental disorder > psychotic 
disorder > mood disorder > anxiety disorder > personality disorder > other psychiatric diagnosis. 
Presence of a diagnosis in an earlier category trumped diagnosis in subsequent categories, i.e., if a 
patient had recorded diagnoses of both a psychotic disorder and an anxiety disorder, psychotic 
disorder was chosen as the main diagnosis.
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In addition, we extracted data on intensity of care need, which included the duration of the EIS 
intervention, the number and duration of inpatient admissions, the number of referrals to crisis and 
home treatment teams for short-term intensive support in the community, and estimated number of 
clinical contacts (using number of entries in the EHR as a proxy). We adjusted all intensity of care 
measures for each patient’s duration of contact with the EIS.
A proportion of the sample had clinical measures of psychiatric illness severity taken at baseline. 
The specific measure taken varied over time, including the SWEMWBS (Short Warwick Edinburgh 
Mental Wellbeing Scale (SWEMWBS) © NHS Health Scotland, University of Warwick and 
University of Edinburgh, 2008, all rights reserved); the Clinical Global Impression (CGI) (Guy, 
1976); and the Brief psychiatric rating scale (BPRS) (Faustman and Overall, 1999). 
3.3 Extraction and coding of variables related to cardiometabolic function and inflammation
Custom-built natural language processing (NLP) software (Cardinal, 2017) was used to extract 
numerical cardiometabolic and inflammatory marker data from unstructured text, e.g. medical notes. 
Blood results were included only if they were recorded around the start date of the EIS involvement 
(+/- 100 days), and if more than one test was recorded within this time frame, the closest to the EIS 
start date was chosen.
3.3.1 Cardiometabolic Biomarkers
Cardiometabolic markers were available for a variable proportion of the sample within the first 100 
days from EIS involvement start, and included systolic/diastolic blood pressure (mm/Hg), body mass 
index (BMI) (kg/m2), glucose (mmol/L), glycated haemoglobin (HbA1c) (mmol/mol), and a full 
lipid profile (total cholesterol (mmol/L) and triglycerides (mmol/L)). Some of the NLP tools for the 
extraction of cardiometabolic marker data were developed specifically for this study. Accuracy and 
reliability for all cardiometabolic markers were satisfactory, as measured by recall (probability of 
retrieving a record given it was relevant; >0.75 for all) and precision (probability of a record being 
relevant, given it was retrieved; >0.90 for all) statistics (see (Osimo et al., 2018) for how these were 
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calculated). High-density lipoprotein (HDL) cholesterol levels were not always recorded, so we used 
the Friedewald equation (Tremblay et al., 2004) to derive this parameter from other lipid levels in 
patients lacking a direct measure.
3.3.2 Inflammatory Markers
We extracted measures of CRP and differential cell counts using methods described previously 
(Osimo et al., 2018). In keeping with previous analyses and data availability, CRP levels were 
categorised as follows: ≤3 mg/L (“non-inflamed”); >3 CRP ≤10 mg/L (“low-grade inflammation”); 
>10mg/L (“suspected infection”). See also Supplementary Methods. 
In addition, we calculated NLR and basophil to lymphocyte (BLR) ratios. 
3.4 Statistical analysis
P-values were adjusted using the Benjamini & Hochberg method. The false-discovery rate (q) was 
set to 0.05, and results were considered significant when corrected P-values were <0.05. All 
statistical analyses were performed in R(R Core Team, 2017). Plots were made using 
ggplot2(Wickham, 2009), using the Cairo R graphics device(Urbanek and Horner, 2005).
3.4.1 Primary analysis
Cardiometabolic and inflammatory markers at baseline were described by subsequent clinical 
outcome and diagnosis. An ANOVA test was used to compare mean values between groups when 
data approximated a normal distribution; a Kruskal-Wallis rank sum test was used for skewed 
continuous data which could not be normalised with log-transformation. 
Logistic regression was used to calculate unadjusted odds ratios (ORs) and 95% confidence intervals 
(95% CIs) for all inflammatory and metabolic markers for participants with poor, compared with 
good, clinical outcome/illness course. For regression, due to the very skewed nature of some of the 
variables, all continuous variables (inflammatory and cardio-metabolic markers) were converted into 
tertiles; the reference category was set to the lowest tertile (≤33th centile). ORs represent the 
9Osimo et al, Inflammation and dysmetabolism in first episode psychosis, 15/09/2020
increase in risk for poor outcome/course for participants for each tertile, with the bottom tertile as the 
reference group.
To examine whether and how confounding may have influenced logistic regression estimates, we 
performed adjusted analyses in several stages. First, we adjusted for sociodemographic factors (age; 
sex; ethnicity). Second, we adjusted for BMI. Finally, we conducted a ‘full’ model including all 
adjustments in the same model.
3.4.2 Sensitivity analyses
Intensity of care need measures were used to validate illness course clinical outcomes. Principal 
components analysis (PCA) was used to identify the major dimensions of variation and covariation 
over immune cell counts, using data from all participants. Correlations between variables 
significantly associated with the primary outcome were explored using the Pearson correlation 
coefficient and test.
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4 Results
4.1 Sample description
A total of 2,352 patients were referred to the CAMEO EIS between January 2013 and November 
2019, of which 1,325 patients were taken on by the service after excluding inappropriate referrals 
and technical errors. Of these, 749 had completed EIS involvement, had not moved our of area and 
were subsequently discharged either to the care of their GP, or an onward referral was made to 
another mental health team for continued support. This sample formed the basis for our analysis of 
long-term clinical outcomes, i.e. the risk set (see Figure 1). The median duration of EIS involvement 
for these patients was 655 days (~1.8 years; interquartile range: 246-797 days). Out of the risk set, 
data on baseline blood biomarkers were available for up to 262 patients (analytic sample). See Table 
1 for the baseline socio-demographic characteristics of the sample. 
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Figure 1: Sample selection
EI: early intervention; N: sample size 
4.2 Clinical outcome/ illness course and intensity of care needs
Out of 749 FEP patients who had completed EIS involvement, 447 patients (59.68%) were 
discharged to the care of their general practitioner (GP) and did not require any secondary care input 
following discharge from the EI service, indicating either remission or a stable condition (good 
clinical outcome/ illness course), while 302 (40.32%) needed support from other secondary mental 
health teams indicating poor clinical outcome/illness course, such as a relapsing/remitting illness or 
treatment resistance (including treatment with clozapine). We found no evidence that these groups 
differed in terms of demographic characteristics or ICD-10 psychiatric diagnosis (see Table 1).
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With regards to intensity of care measures taken during EIS involvement, patients with poor outcome 
had a significantly longer duration of EIS involvement (adjusted p=0.01), higher clinical contact rate 
(adjusted P<0.0001), higher EIS-duration-adjusted number of hospitalisations, higher number of 
days in hospital (all adjusted P<0.0001), and higher number of high-intensity treatment episodes 
under crisis and home treatment teams (adjusted P<0.05), compared with those with a good outcome 
(see Supplementary Table 1).
A proportion of the patients had illness severity measures taken at baseline. Overall, illness severity 
scores did not differ between patients showing good or poor outcome at discharge (see 
Supplementary Table 2).
4.3 Associations between baseline cardiometabolic measures and clinical outcome/ illness 
course and psychiatric diagnosis at follow-up
Table 2 and Figure 2 describe the distribution of cardiometabolic measures at baseline by 
subsequent clinical outcome. Higher baseline triglyceride levels were significantly associated with 
poor outcome/ illness course at follow-up (P=0.004; BH-adjusted P=0.03). Similarly, logistic 
regression analyses showed evidence for an association between higher baseline triglycerides levels 
and poor clinical outcome/illness course at follow-up. The unadjusted OR for poor outcome for those 
in the top, compared with bottom, tertile of triglycerides levels at baseline was 2.96 (95% CI, 1.32-
6.93). Evidence for this association remained after adjusting for potential confounders (adjusted 
OR=7.32; 95%CI, 2.26-28.06); see Table 4. However, other baseline cardiometabolic measures were 
not associated with the subsequent clinical outcome at follow-up (Tables 2, 4 and Figure 2). 
Baseline cardiometabolic markers were not associated with any specific psychiatric diagnosis at 
follow-up (Supplementary Figure 1).
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Figure 2: Baseline cardio-metabolic marker measures in groups with good and poor clinical 
outcome/ illness course at follow-up
Legend: The figure describes baseline cardio-metabolic marker measures in the EI sample by clinical 
outcome. Boxplots show median and interquartile range, with the outer violin shape showing the density 
distribution. Discharge to primary care represents a good outcome (teal); requiring specialist care upon 
discharge represents a worse outcome (red). The number of patients (N) is indicated for each marker. The 
orange dotted line represents the higher reference range value, the blue dotted line the lower reference range 
value for each marker.
Differences were tested using Kruskal-Wallis rank sum tests, and the p values shown are already adjusted for 
multiple comparisons using the BH method. HbA1c: glycated haemoglobin; HDL: high-density lipoprotein; 
LDL: low-density lipoprotein; BP: blood pressure; BMI: body mass index
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4.4 Associations between baseline differential cell counts and clinical outcome/ illness course 
and psychiatric diagnosis at follow-up
Table 3 and Figure 3 describe the distribution of differential cell counts at baseline by subsequent 
clinical outcome. Lower baseline basophil count and BLR were significantly associated with poor 
clinical outcome/ illness course (BH-adjusted P=0.001 and P<0.001, respectively). Baseline 
monocyte counts were higher in the group with poor outcome; however, this was not significant after 
correcting the P-value for multiple testing. 
Logistic regression analyses showed evidence for an association between multiple baseline cell 
counts and poor clinical outcome/ illness course at follow-up, including for BLR, monocytes, 
basophils, lymphocytes and platelets (Table 4). For BLR, the unadjusted OR for poor outcome for 
those in the top, as compared with those in the bottom tertile was 0.19 (95% CI, 0.07-0.43), which 
remained significant after adjusting for confounders (adjusted OR=0.14; 95% CI, 0.02-0.58). For 
monocytes, the adjusted OR for poor outcome for those in the top, as compared with those in the 
bottom tertile, was 2.78 (95% CI, 1.02-8.06). For basophils, the adjusted OR for poor outcome for 
those in the middle, as compared with those in the bottom tertile was 0.24 (95% CI, 0.07-0.72). For 
lymphocytes, the adjusted OR for poor outcome for those in the middle, as compared with those in 
the bottom tertile, was 3.49 (95% CI, 1.15-12.11). For platelets, the unadjusted OR for poor outcome 
for those in the top, as compared with those in the bottom tertile was 2.88 (95% CI, 1.29-6.63), but it 
became non-significant after adjusting for BMI. Other baseline cell counts were not associated with 
subsequent clinical outcomes at follow-up (Tables 3, 4 and Figure 3). 
With regards to the associations between baseline cell counts and subsequent psychiatric diagnoses, 
Supplementary Figure 2 shows that lymphocyte counts varied significantly between diagnostic 
groups, with higher counts in primary psychosis compared with mood disorders (overall BH-adjusted 
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P=0.02). Baseline NLR also differed between subsequent diagnoses: NLR was higher in patients 
diagnosed with a mood disorder or psychosis as compared to those with other/no available diagnoses 
(overall BH-adjusted P=0.03), but no significant difference was present directly comparing patients 
diagnosed with a mood disorder and psychosis (P=0.36). Other baseline cell counts were not 
significantly different between diagnostic groups.
Many of the inflammatory measures were correlated, so we also summarised cell count data using 
principal components analysis. Principal components 1 and 2 of a PCA of baseline differential cell 
counts were not significantly different by subsequent diagnosis or illness course; more details are 
described in the Supplementary results. 
4.4.1 Correlation between cardiometabolic and inflammatory measures
Correlations between baseline cardiometabolic and inflammatory measures were explored for the 
sample. These can be found as Supplementary Figure 3.
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Figure 3: Baseline differential cell counts in groups with good and poor clinical outcome/ illness 
course at follow-up
Legend: The figure shows a comparison between cell counts in the EI sample by clinical outcome. Boxplots 
show median and interquartile range, with the outer violin shape showing the full distribution of data. 
Discharge to primary care represents a good outcome (teal); requiring specialist care upon discharge 
represents a worse outcome (red). The number of patients (N) is indicated for each marker. The orange dotted 
line represents the higher reference range value, the blue dotted line the lower reference range value for each 
marker.
Differences were tested using Kruskal-Wallis rank sum tests, and the p values shown are already adjusted for 
multiple comparisons using the BH method. NLR: neutrophil to lymphocyte ratio; BLR: basophil to 
lymphocyte ratio.
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4.5 Associations between baseline CRP levels and clinical outcome/ illness course and 
psychiatric diagnosis at follow-up
Data on both baseline plasma CRP levels and subsequent clinical outcome/illness course were 
available for 52 patients only. Of these, 14 (26.92%) showed evidence of low-grade inflammation 
(CRP>3mg/L but ≤10mg/L), and 17 (32.69%) had evidence of suspected infection (CRP>10mg/L). 
The prevalence of low-grade inflammation (CRP 3-10mg/L) at baseline was somewhat higher in the 
group with subsequent poor clinical outcome/illness course (28.57%) than in those with a good 
outcome (25.81%); however, this difference was not statistically significant (2-sided Fisher's exact 
test P=0.68). Baseline inflammation was not significantly associated with any specific diagnosis 
subsequently at follow-up (P=0.36).
Logistic regression analyses showed no evidence for an association between baseline levels of CRP 
and poor clinical outcome/ illness course at follow-up. Table 4 shows that the unadjusted OR for 
poor outcome for patients with CRP>10mg/L, as compared to those with CRP≤3mg/L, was 1.78 
(95% CI, 0.48-6.83). ORs adjusted by BMI could not be calculated due to a small sample size.
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Table 1: Sociodemographic characteristics and diagnosis of patients treated by the early intervention service
Domain Characteristic Total under EIS Sample with 
longitudinal 
psychiatric 
outcome data
Good outcome 
(discharged to 
primary care 
from EIS)
Poor outcome 
(continued 
psychiatric care 
after EIS)
Difference 
between groups - 
test statistic
Sample size 1,325 749 447 (59.68%) 302 (40.32%)
Age, mean (SD) years 27.35 (10.51) 26.71 (10.34) 27.02 (11.06) 26.26 (9.17) F= 0.96, df=1, 
p=0.33
Male sex, n (%) 823 (62.11%) 458 (61.15%) 264 (59.06%) 194 (64.24%) χ2 = 2.03; df = 1; 
p=0.15
Ethnicity, n (%)
White
Asian
Black
Mixed
Unknown
882 (66.57%)
86 (6.49%)
46 (3.47%)
62 (4.68%)
249 (18.79%)
511 (68.22%)
48 (6.41%)
20 (2.67%)
39 (5.21%)
131 (17.49%)
303 (67.79%)
29 (6.49%)
10 (2.24%)
24 (5.37%)
81 (18.12%)
208 (68.87%)
19 (6.29%)
10 (3.31%)
15 (4.97%)
50 (16.56%)
χ2 = 1.13; df = 4; 
p=0.89
So
ci
o-
de
m
og
ra
ph
ic
 fa
ct
or
s
Marital status, n (%)
Married, Cohabiting, or in a Partnership
Single, Other or NA
169 (12.75%)
1156 (87.25%)
93 (12.42%)
656 (87.58%)
52 (11.63%)
395 (88.37%)
41 (13.58%)
261 (86.42%)
χ2 = 0.63; df = 1; 
p=0.43
F2x (Schizophrenia, schizotypal, delusional, 
and other non-mood psychotic disorders)
548 (41.36%) 341 (45.53%) 192 (42.95%) 149 (49.34%)
F3x (Mood disorders) 171 (12.91%) 106 (14.15%) 65 (14.54%) 41 (13.58%)
D
ia
gn
os
is
Other diagnoses or not coded 606 (45.74%) 302 (40.32%) 190 (42.51%) 112 (37.09%)
χ2 = 3.04; df = 2; 
p=0.22
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Table 2: Baseline biochemical and cardio-metabolic factors in patients under the early intervention service (EIS) and in groups with good or poor clinical 
outcome/ illness course on discharge from EIS
Total Baseline Sample
N=1,325
Sample with longitudinal 
psychiatric outcomes
N=749
Good outcome 
(discharged to 
primary care from 
EIS)
N=447 (59.68%)
Poor outcome 
(continued 
psychiatric care 
after EIS)
N=302 (40.32%)
Characteristic N 
with 
data
Median (25th-
75th centile)
N with 
data
Median (25th-75th 
centile)
Median (25th-75th 
centile)
Median (25th-75th 
centile)
Difference 
between groups 
- test statistic1
BH-
corrected 
P-value
Random glucose (mmol/l) 385 5.0 (4.5-5.9) 194 5.0 (4.53-5.97) 5.0 (4.60-5.80) 5.1 (4.5-6.0) K-W χ2=0.01, df 
= 1, p=0.91
0.98
HbA1c (mmol/l) 119 34.0 (32.5-37.0) 48 33.0 (32.0-37.0) 33.0 (32.0-37.0) 34.0 (33.0-35.5) K-W χ2=0.57, df 
= 1, p=0.45
0.98
Triglycerides (mmol/l) 341 1.0 (0.7-1.6) 167 1.0 (0.7-1.7) 0.9 (0.7-1.6) 1.3 (0.88-2.05) K-W χ2=8.47, df 
= 1, p=0.0036**
0.03*
Total cholesterol (mmol/l) 351 4.4 (3.8-5.1) 164 4.5 (3.9-5.1) 4.5 (3.8-5.1) 4.4 (3.9-5.0) K-W χ2<0.01, df 
= 1, p= 0.98
0.98
HDL (mmol/l) 299 1.42 (1.15-1.83) 138 1.47 (1.20-1.87) 1.48 (1.20-1.90) 1.45 (1.15-1.76) K-W χ2=0.08, df 
= 1, p= 0.77
0.98
LDL (mmol/l) 304 2.35 (1.90-2.91) 145 2.37 (2.00-2.90) 2.50 (2.03-3.06) 2.20 (1.89-2.60) K-W χ2=3.9, df 
= 1, p= 0.05
0.22
Systolic BP (mmHg) 497 120 (111-130) 262 120 (111-130) 120 (111-130) 120 (112-131) K-W χ2<0.01, df 
= 1, p= 0.95
0.98
Diastolic BP (mmHg) 494 77 (70-86) 262 76 (69-85) 76 (70-85) 76 (69-86) K-W χ2<0.01, df 
= 1, p= 0.97
0.98
BMI (kg/m2) 397 23.3 (20.2-26.7) 197 23.0 (20.1-27.0) 23.0 (20.7-26.9) 22.5 (19.5-27.2) K-W χ2=0.54, df 
= 1, p= 0.46
0.98
Legend: BH-adjusted p: p adjusted for multiple comparisons using the Benjamini and Hochberg method
* significant result (p<0.05); ** significant result (p<0.01)
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Table 3: Baseline differential cell counts in patients under the early intervention service (EIS) and in groups with good or poor clinical outcome/ illness course 
on discharge from EIS
Total Baseline Sample
N=1,325
Sample with longitudinal 
psychiatric outcomes
N=749
Good outcome 
(discharged to 
primary care 
from EIS)
N=447 (59.68%)
Poor outcome 
(continued 
psychiatric care 
after EIS)
N=302 (40.32%)
Cell Count N 
with 
data
Median (25th-75th 
centile)
N 
with 
data
Median (25th-75th 
centile)
Median (25th-
75th centile)
Median (25th-
75th centile)
Difference 
between groups - 
test statistic1
BH-
correcte
d P-
value
Red blood cells (RBC)
x 1012 per litre
387 4.80 (4.46-5.14) 199 4.80 (4.46-5.14) 4.80 (4.4-5.13) 4.78 (4.41-5.1) K-W χ2=0.6, df = 
1, p=0.44
0.44
Platelets
x 109 per litre
283 248 (202-292) 160 251 (206-289) 235 (199-277) 256 (225-293) K-W χ2=3.71, df = 
1, p=0.05
0.12
Neutrophils 
x 109 per litre
424 4.1 (3.0-5.6) 226 4.2 (3.0-5.7) 4.0 (2.9-5.6) 4.5 (3.4-5.9) K-W χ2=1.57, df = 
1, p=0.21
0.32
Lymphocytes 
x 109 per litre
399 1.75 (1.35-2.28) 211 1.80 (1.40-2.20) 1.75 (1.31-2.20) 1.87 (1.54-2.25) K-W χ2=1.88, df = 
1, p= 0.17
0.31
Monocytes 
x 109 per litre
383 0.47 (0.36-0.62) 203 0.50 (0.40-0.70) 0.46 (0.37-0.62) 0.56 (0.40-0.70) K-W χ2=4.53, df = 
1, p= 0.03*
0.10
Basophils 
x 109 per litre
372 0.02 (0.00-0.04) 196 0.02 (0.00-0.04) 0.02 (0.00-0.04) 0.00 (0.00-0.03) K-W χ2=13.3, df = 
1, p= 0.0003 **
0.001 
**
Eosinophils 
x 109 per litre
386 0.11 (0.08-0.20) 205 0.11 (0.09-0.20) 0.11 (0.08-0.20) 0.13 (0.10-0.20) K-W χ2=0.87, df = 
1, p= 0.35
0.42
Neutrophil to lymphocyte 
ratio (NLR)
391 2.27 (1.58-3.33) 207 2.20 (1.54-3.26) 2.19 (1.52-3.02) 2.27 (1.70-3.40) K-W χ2=0.8, df = 
1, p= 0.37
0.42
Basophil to lymphocyte 
ratio (BLR)
368 0.01 (0.00-0.03) 193 0.01 (0.00-0.02) 0.02 (0.00-0.03) 0.00 (0.0-0.01) K-W χ2=15.8, df = 
1, p= 0.000071**
<0.001 
**
Legend: BH-adjusted p: p adjusted for multiple comparisons using the Benjamini and Hochberg method
* significant result (p<0.05); ** significant result (p<0.01)
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Table 4: Odds ratios (95% CI) for poor clinical outcome/illness course on discharge from the early intervention service associated with baseline biochemical, 
cardio-metabolic and inflammatory measures
Predictor N with 
data
Measure Tertile 
[reference= bottom 
tertile]
(Cut-off values)
Odds ratios (95% CI) for poor clinical outcome/illness course 
Cardiometabolic 
markers
Unadjusted 
Model
Adjusted for
age, sex, ethnicity
Adjusted for
BMI
Adjusted for age, sex, 
ethnicity, BMI
Middle (>4.7, ≤5.4) 0.65 (0.30-1.39) 0.65 (0.30-1.39) 0.56 (0.16-1.87) 0.54 (0.15-1.87)Random glucose 
(mmol/l) 194 Top (>5.4) 1.07 (0.52-2.23) 1.06 (0.50-2.25) 1.29 (0.40-4.25) 1.50 (0.43-5.42)
Middle (>33, ≤36) 1.31 (0.16-8.23) 1.13 (0.12-8.27) N/A* N/A*HbA1c (mmol/l) 48
Top (>36) 0.95 (0.12-5.74) 1.99 (0.17-19.24) N/A* N/A*
Middle (>0.8, ≤1.4) 1.58 (0.64-3.91) 1.62 (0.66-4.02) 2.15 (0.53-8.77) 2.12 (0.52-8.72)Triglycerides 
(mmol/l) 167 Top >1.4 2.96 (1.32-6.93) 3.26 (1.42-7.86) 6.06 (2.03-21.02) 7.32 (2.26-28.06)
Middle (>4, ≤4.9) 1.02 (0.46-2.29) 0.99 (0.44-2.24) 1.51 (0.50-4.81) 1.47 (0.48-4.74)Total cholesterol 
(mmol/l) 164 Top (>4.9) 0.84 (0.35-1.98) 0.82 (0.33-2.02) 1.65 (0.47-5.97) 1.64 (0.44-6.30)
Middle (>1.22, ≤1.63) 1.36 (0.55-3.43) 1.30 (0.52-3.32) 1.84 (0.54-6.88) 1.87 (0.54-7.09)HDL (mmol/l) 138
Top (>1.63) 0.88 (0.34-2.30) 0.86 (0.32-2.27) 1.07 (0.29-4.19) 1.04 (0.28-4.19)
Middle (>2.04, ≤2.73) 1.29 (0.56-3.03) 1.26 (0.55-2.96) 0.91 (0.27-3.11) 0.89 (0.26-3.09)LDL (mmol/l) 145
Top (>2.73) 0.41 (0.15-1.09) 0.40 (0.14-1.08) 0.81 (0.24-2.69) 0.80 (0.23-2.68)
Middle (>115, ≤127) 1.00 (0.55-1.82) 0.97 (0.53-1.78) 1.08 (0.46-2.55) 1.07 (0.44-2.59)Systolic BP 
(mmHg) 262 Top (>127) 0.98 (0.53-1.81) 1.02 (0.54-1.95) 1.28 (0.56-2.96) 1.42 (0.57-3.59)
Middle (>72, ≤82) 0.75 (0.41-1.36) 0.81 (0.44-1.50) 1.24 (0.54-2.86) 1.40 (0.60-3.32)Diastolic BP 
(mmHg) 262 Top (>82) 0.95 (0.51-1.74) 1.08 (0.57-2.06) 1.19 (0.51-2.81) 1.37 (0.57-3.36)
Middle (>21.4, ≤25) 0.71 (0.33-1.51) 0.84 (0.38-1.86) N/A** N/A**BMI (kg/m2) 197
Top (>25) 0.85 (0.41-1.75) 0.90 (0.43-1.88) N/A** N/A**
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Predictor N with 
data
Measure Tertile 
[reference= bottom 
tertile]
(Cut-off values)
Odds ratios (95% CI) for poor clinical outcome/illness course
Inflammatory 
markers
Unadjusted 
Model
Adjusted for
age, sex, ethnicity
Adjusted for
BMI
Adjusted for age, sex, 
ethnicity, BMI
Middle (>4.6, ≤5) 1.12 (0.56-2.24) 1.21 (0.59-2.52) 1.15 (0.41-3.24) 1.08 (0.36-3.21)Red blood cells 
(RBC) count 199 Top (>5) 0.65 (0.31-1.36) 0.77 (0.34-1.74) 0.75 (0.24-2.28) 0.67 (0.18-2.45)
Middle (>216, ≤271) 2.00 (0.91-4.52) 1.85 (0.82-4.23) 0.95 (0.30-3.05) 0.94 (0.29-3.04)Platelets count 160
top (>271) 2.88 (1.29-6.63) 2.63 (1.16-6.16) 2.85 (0.92-9.35) 3.09 (0.97-10.50)
Middle (>3.44, ≤5.05) 1.84 (0.92-3.77) 1.82 (0.89-3.78) 1.84 (0.65-5.40) 1.90 (0.66-5.65)Neutrophils count 226
Top (>5.05) 1.65 (0.83-3.33) 1.49 (0.73-3.08) 2.37 (0.85-6.91) 2.42 (0.83-7.44)
Middle (>1.47, ≤2.06) 2.23 (1.09-4.73) 2.39 (1.15-5.15) 3.35 (1.13-11.42) 3.49 (1.15-12.11)Lymphocytes 
count 211 Top (>2.06) 1.70 (0.80-3.72) 1.79 (0.83-3.95) 2.30 (0.71-8.28) 2.41 (0.73-8.77)
Middle (>0.4, ≤0.57) 1.55 (0.72-3.38) 1.52 (0.70-3.34) 0.96 (0.26-3.29) 0.91 (0.24-3.15)Monocytes count 203
Top (>0.57) 2.33 (1.17-4.75) 2.35 (1.17-4.82) 2.74 (1.01-7.88) 2.78 (1.02-8.06)
Middle (>0, ≤0.04) 0.32 (0.16-0.64) 0.31 (0.15-0.61) 0.26 (0.08-0.76) 0.24 (0.07-0.72)Basophils count 196
Top (>0.04) 0.27 (0.10-0.62) 0.25 (0.10-0.60) 0.47 (0.12-1.56) 0.40 (0.10-1.39)
Middle (>0.1, ≤0.2) 0.66 (0.32-1.33) 0.72 (0.35-1.47) 0.75 (0.25-2.06) 0.77 (0.26-2.16)Eosinophils count 205
Top (>0.2) 1.29 (0.62-2.63) 1.43 (0.68-3.00) 1.34 (0.43-3.91) 1.41 (0.44-4.29)
Middle (>1.86, ≤2.9) 1.50 (0.76-3.03) 1.41 (0.70-2.88) 1.50 (0.54-4.30) 1.45 (0.51-4.20)Neutrophil to 
lymphocyte ratio 
(NLR)
207 Top (>2.9) 1.25 (0.60-2.60) 1.15 (0.54-2.47) 1.44 (0.49-4.30) 1.42 (0.46-4.45)
Middle (>0, ≤0.02) 0.44 (0.21-0.90) 0.41 (0.19-0.85) 0.48 (0.16-1.33) 0.43 (0.14-1.22)Basophil to 
lymphocyte ratio 193 Top (>0.02) 0.19 (0.07-0.43) 0.19 (0.07-0.43) 0.16 (0.02-0.65) 0.14 (0.02-0.58)
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(BLR)
4-10mg/L 1.50 (0.37-6.17) 1.72 (0.35-8.78) N/A* N/A*CRP 52
>10mg/L 1.78 (0.48-6.83) 2.30 (0.55-10.44) N/A* N/A*
Note: All values were divided into tertiles. Values are the OR for the middle or top tertile over the reference (bottom) tertile for each variable. In bold are 
significant results 
* insufficient sample with all independent variables available
** BMI cannot be both independent variable and predictor
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5 Discussion
Using real-world clinical data from electronic health records (EHR) from an EI service in 
England, we examined clinical outcomes/illness course and intensity of care need in a sample 
of patients with FEP. The majority of patients with FEP had favourable long-term clinical 
outcomes, as ~60% were discharged to primary care with no ongoing involvement of 
secondary mental health services. 
We tested for associations between blood cardiometabolic and inflammatory markers at 
baseline and clinical outcomes at follow-up. Higher triglyceride levels were associated with a 
higher risk of a subsequent poor clinical outcome/ illness course. We also found that higher 
monocyte, lymphocyte and platelet counts were directly associated with a subsequent poor 
clinical outcome/illness course. Basophil counts and BLR were protective. Some of these 
ORs did not consistently reach the significance threshold for all levels of adjustment which 
could be due to limited sample size. Other baseline measures, including glucose, blood 
pressure, BMI, cholesterol levels, other cell counts, CRP levels and the first two principal 
components of differential cell counts were not significantly associated with psychiatric 
illness course. In terms of diagnosis, lymphocyte counts were significantly lower, and NLR 
higher, in patients subsequently diagnosed with a primary mood-disorder related psychosis 
(unipolar depression or bipolar disorder).
To our knowledge, this is the first study measuring longitudinal associations between 4 
demographic measures, 10 immune, and 9 metabolic baseline predictors and long-term 
psychiatric outcomes including diagnosis and illness course in a large sample of patients with 
FEP. Our results suggest that multiple blood-based markers may have a prognostic potential 
for patients with a FEP. Several previous cross-sectional studies measured immune and 
metabolic measures in FEP. However, only a handful of longitudinal studies exist that have 
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measured markers at baseline and psychiatric outcomes at follow-up in FEP. These tended to 
be studies involving a small cohort followed up for up to one year (Mondelli et al., 2015; 
Nettis et al., 2019). In this study we were able to harness EHR data to extract baseline data – 
originally collected for clinical reasons – and use it in conjunction with diagnosis and team 
referral data to study associations with long-term clinical outcomes in a much larger cohort of 
749 FEP patients.
In this study we classified clinical outcome/illness course using a binary descriptor based on 
whether FEP patients needed further secondary care support following discharge from the 
EIS (poor clinical outcome/ illness course) or not (good outcome). These two groups were 
not significantly different in terms of psychiatric diagnosis, sociodemographic characteristics 
and baseline severity of illness. However, patients with a poor outcome had higher intensity 
of care needs during their involvement with EIS as reflected by higher number of clinical 
contacts, hospitalisations and number of high-intensity crisis and home treatment team 
support, indicating that discharge destination is a useful proxy for prognosis. 
Our study does not seek to establish whether these associations represent causal relationships, 
but to document associations, which could inform future research into causes, interventions 
or prognostics. Our study leaves open the possibility that some of the documented 
associations could be causal, and therefore potential treatment targets, or epiphenomenal, 
reflecting the fact that patients with worse prognosis have other biological or social 
associations that predispose them to differential baseline biomarker levels. Irrespective of 
whether or not the relationships are causal, biomarker associations with important clinical 
outcomes could, if replicated, potentially contribute to clinical care as prognostic markers.
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Our findings of an association between elevated triglyceride levels and risk of a worse 
outcome are compatible with a previous study of 42 FEP patients, which found that a 
principal component factor including immune and metabolic factors (CRP, triglyceride levels 
and BMI) was related to worse outcomes (higher PANSS scores) at about one year (Nettis et 
al., 2019). Previous cross-sectional evidence has also consistently associated FEP with higher 
triglyceride levels, without being able to correlate the finding with illness course (Perry et al., 
2018; Pillinger et al., 2017). It is therefore likely that there is an association between higher 
triglycerides and FEP, and in this study we also find – within FEP – an association between 
higher triglycerides and a more severe illness course. It is unclear how triglyceride levels 
could influence psychiatric clinical outcomes, but our results show that common 
demographic factors or BMI are unlikely to be sole mediators of this association. 
Triglycerides, which are known to play a role in the development of insulin resistance (Banks 
et al., 2018), might warrant consideration as a potential biological link between schizophrenia 
and cardiometabolic disease, which may be genetic (Lin and Shuldiner, 2010). 
We also found evidence of an inverse association between basophil counts/BLR and a worse 
psychiatric illness course. Furthermore, our sensitivity analyses show that the association 
with BLR was not fully explained by demographic factors or BMI. For basophils, the 
adjustment for BMI attenuated the association and 95% CI included the null, but this could 
be due to a reduction in sample size from 195 in unadjusted to 109 in BMI-adjusted analyses. 
It is also interesting to note that basophil counts did not correlate with any other measures, 
and could therefore explain a different portion of the variance from other measures. This 
finding is new, and, to our knowledge, basophil counts have not been previously studied in 
relation to clinical outcomes in FEP. Two previous cross-sectional studies comparing 
basophil counts in FEP with healthy controls showed no difference in the two groups 
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(Jackson and Miller, 2019). BLR is a somewhat under-researched measure, and a low BLR 
has previously been described as associated with most systemic autoimmune rheumatic 
diseases (Yang et al., 2017); no associations have been made with psychiatric illness before.
Both basophil counts and triglyceride levels appear to be involved in the insulin resistance 
and diabetes pathways (Harsunen et al., 2013; Koyama et al., 1997; Lee et al., 2014), and, as 
discussed earlier, there are promising associations between insulin resistance/diabetes and 
psychosis. Basophil counts should be investigated further in relation to psychosis, and with a 
particular outlook on illness course.
We also found variable degrees of evidence for associations between baseline monocyte, 
lymphocyte and platelet counts and a worse psychiatric outcome, although platelets and 
lymphocyte associations became non-significant in adjusted analyses. These three cell counts 
were strongly correlated. Monocytes are known to be elevated in FEP, while lymphocytes 
were found to be non-significantly elevated in previous research (Jackson and Miller, 2019). 
However, Mendelian randomisation analyses have shown evidence for potential a causal 
association between higher lymphocyte counts and schizophrenia (Astle et al., 2016). We add 
to this evidence by reporting of the potential value of measuring lymphocytes as a prognostic 
marker in FEP. 
Finally, in this study we did not find a significant association between elevated CRP and 
psychotic illness course. This result is perhaps surprising since there is a wealth of cross 
sectional (Miller et al., 2014; Pillinger et al., 2018) and longitudinal (Khandaker et al., 2014) 
evidence for an association between elevated CRP and psychosis, including with prognosis 
(Nettis et al., 2019). However, our findings may also be explained by the limited power in 
our CRP analysis due to data unavailability, as discussed in the limitations section below. 
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Furthermore, this study did not find a significant association between BMI and psychiatric 
illness course, in contrast to Nettis and colleagues (Nettis et al., 2019). Previous studies have 
reported associations between BMI and psychosis. Lower BMI in childhood is associated 
with later development of non-affective psychosis(Sormunen et al., 2018). There is also 
evidence for a genetic correlation between BMI and schizophrenia (Bulik-Sullivan et al., 
2015). Our negative finding could therefore be a type 2 error, or it could a true finding related 
to specific population characteristics of our cohort.
5.1 Strengths and limitations
This work is based on a large sample of 749 FEP patients, with a follow-up of up to 5 years 
(median of ~2 years). As opposed to previous studies which have recruited patients and 
assigned psychiatric diagnoses based on one assessment, in this study patients were enrolled 
in a years-long process of assessment and treatment within a specialised EI in psychosis 
team, which fosters greater confidence in the psychiatric phenotype for people enrolled in 
this study. This guarantees a high degree of homogeneity of the sample with regards to the 
psychiatric presenting syndrome. Another strength of this study, as compared to studies 
selected for research on specific criteria, is the naturalistic study design, including a large 
number of consecutive referrals with very little possibility of selection bias. As the only EIS 
for FEP in Cambridgeshire, our CAMEO sample covers a large proportion of all incident 
cases of first episode psychosis in a geographically defined catchment area. Further strengths 
include the use of a large number of biomarkers, including some previously under-studied in 
FEP and psychosis in general, such as basophils, eosinophils, platelets, and RBCs. 
Furthermore, we used clinical laboratory measures, so we have a high confidence in the high 
accuracy and precisions of our measures, and as to their clinical applicability.
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A limitation of this work is the lack of antipsychotic medication data at baseline. 
Antipsychotics could influence the levels of cardiometabolic markers. However, most 
patients admitted to CAMEO are medication naïve or minimally treated, and only patients 
who have been taking antipsychotic medication for less than 6 months are accepted by the 
team. Bloods tests were carried out within 100 days of referral to the team so it’s likely that 
some patients would have been started on antipsychotic medication during this time, though 
the duration of treatment is likely to be relatively short.
Among the limitations, this design does mean that a variable sample size is available for each 
measure, due to clinician ordering decisions, patient refusal rates, and because of differences 
in lab ordering protocols for newly admitted patients over time. In statistical terms, variable 
sample sizes for different measures means limited power for multi-variable analyses. More 
specifically, when applying stepwise adjustment, such as we have done for BMI, adjusted 
analyses relied on a smaller sample than un-adjusted ones, therefore making it more likely 
that negative adjusted findings might suffer from a type 2 statistical error. Some evidence for 
this can be seen in Table 4, where a number of ORs are relatively high, but adjustment causes 
a widening of the 95%CIs to the point of including the null. Furthermore, only a small 
proportion of the sample had baseline psychometric information on severity available.
Specifically for CRP analyses we did not have an adequately large sample due to missing 
data. Consequently, our negative findings with regards to the associations between CRP 
levels and outcomes could be reflecting a type 2 error due to low power. 
Other limitations of a clinical sample are the unavailability of potentially relevant 
information, such as data about physical activity levels, smoking or alcohol use.
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5.2 Conclusions and future directions
In this longitudinal study we report that higher triglyceride levels, higher platelet, monocyte 
and lymphocyte counts, and lower basophil counts and BLR at baseline are associated with a 
poor clinical outcome/ illness course in FEP patients in 1-5 years. These findings need 
replication in other samples, and could inform the development of algorithms for the 
prediction of prognosis of long-term outcomes in FEP in clinical settings.
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Highlights
 About 60% of patients with a first episode of psychosis showed a favourable long term 
psychiatric clinical outcome (i.e., discharge to primary care).
 Patients showing favourable versus unfavourable outcomes did not differ in terms of 
demographic characteristics or ICD-10 psychiatric diagnosis.
 Baseline triglyceride levels, as well as monocyte, lymphocyte and platelet counts showed a 
direct association with an unfavourable outcome (i.e., need for ongoing specialist psychiatric 
care).
 A higher baseline basophil count and basophil:lymphocyte ratio were associated with a 
favourable outcome.
 Baseline CRP levels and BMI were not associated with long-term psychiatric outcome.
